Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

By R. Motzer, M. Michaelson, B. Redman, G. Hudes, G. Wilding, R. Figlin, M. Ginsberg, Sindy T. Kim, C. Baum, S. Deprimo and 5 more. Journal of Clinical Oncology, 2006

1,640 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7915ed1fdaf5304b8851b2196c9802124900c201

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006, background): “However, despite some promising looking possibilities, such as the increase in levels of circulating VEGF and/or the VEGF family member placental growth factor ( PLGF ), and the concurrent decrease in levels of soluble VEGF receptor2 ( VEGFR2 ) that is seen during therapy with the VEGF receptor-targ”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…in the MARINA and ANCHOR trials 207 , 208 , resulting in FDA approval for neovascular AMD • Sunitinib demonstrates anti-tumour activity as a second-line therapy in a Phase II trial on metastatic renal carcinoma 19,116,271 and in Phase I–III clinical trials for gastrointestinal stromal tumour 21 .”
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, positive): “Additionally, the small-molecule inhibitors sorafenib and sunitinib, which target multiple receptor tyrosine kinases including VEGF receptors, have shown efficacy in treating metastatic renal cell carcinoma (Escudier et al., 2007; Motzer et al., 2006).”
Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “Small-molecule inhibitors of VEGFR have been developed, which inhibit its receptor tyrosine kinase activity and often other kinases as well(for example, refs”
Molecular basis for sunitinib efficacy and future clinical development (2007, positive): “In a pooled analysis of two independent, open-label Phase II studies of second-line sunitinib (summarized in Table 2 ), the objective response rate (ORR) was 42”
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007, result): “Consistent with previous reports on the effects of anti-VEGF agents (Motzer et al., 2006; Willett et al., 2005; J. Drevs et al., 2005, J. Clin.”
Accessories to the crime: functions of cells recruited to the tumor microenvironment. (2012, positive): “Similarly, TAM production of the VEGF family member PIGF stimulates angiogenesis in some tumors (Rolny et al., 2011) and thus TAMs may present a mechanism for acquiring resistance to anti-VEGF-A/VEGFR therapies (Fischer et al., 2007; Motzer et al., 2006; Willett et al., 2005).”